Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R130 in Relapsed/Refractory Head and Neck Cancer
NCT05830240Phase 1Recruiting
- Sponsor
- Shanghai Yunying Medical Technology Co., Ltd.
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of R130 in head and neck cancer (HNC), sponsored by Shanghai Yunying Medical Technology Co., Ltd. Primary endpoints: Safety Profile Measured by Grade >=3 CTCAE v5.0 up to 6 months and Systemic immune response up to 6 months. Started Mar 2023; status: recruiting.
02
Drugs
R130
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT05830240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05830240.